The potency of blumeatin and luteolin as caspase-1 inhibitor by molecular docking
Pharmacy Reports · 2022
DOI: 10.51511/pr.22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy Reports, 2022. Verfasst von I Putu Ari Anggara Catur Pratama und 4 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kementerian Riset, Teknologi dan Pendidikan Tinggi.
Abstract (Originalsprache)
COVID-19 infection induces inflammation by increasing cytokines such as IL-1b, IL-6, IL-18, IFN-γ, and TNF-α. IL-1b is generated by the involvement of caspase-1. Therefore, caspase-1 inhibitor can be potential for inflammation therapy caused by COVID-19 infection. This study aims to determine the potential of blumeatin and luteolin as anti-inflammatory agents by inhibiting caspase-1 using a molecular docking approach. This study was carried out by caspase-1 (PDB ID: 1RWK) preparation, blumeatin and luteolin structure optimization, docking protocol validation, and docking of blumeatin and luteolin on caspase-1. Bluematin and luteolin had a binding affinity of -5,63 kcal/mol and -5,93 kcal/mol, lower than Q158 native ligand (-3.92 kcal/mol). Similar amino acid residues in hydrogen bonds interaction were observed between Q158 native ligand, blumeatin, and luteolin with caspase-1 (GLN 283 and ARG 179). Blumeatin and luteolin are potentially anti-inflammation agents through the inhibition of the caspase-1 in silico.
Förderung
- Kementerian Riset, Teknologi dan Pendidikan Tinggi
Zitieren
APA
Pratama, I. P. A. A. C., Putra, I. M. H., Pujasari, L. W. S., Dewi, K. D. M. S., & Laksmiani, N. P. L. (2022). The potency of blumeatin and luteolin as caspase-1 inhibitor by molecular docking. Pharmacy Reports. https://doi.org/10.51511/pr.22
Vancouver
Pratama IPAAC, Putra IMH, Pujasari LWS, Dewi KDMS, Laksmiani NPL. The potency of blumeatin and luteolin as caspase-1 inhibitor by molecular docking. Pharmacy Reports. 2022. doi:10.51511/pr.22
BibTeX
@article{Pratama2022,
author = {Pratama, I Putu Ari Anggara Catur and Putra, I Made Harimbawa and Pujasari, Luh Wayan Sita and Dewi, Komang Dian Merta Sari and Laksmiani, Ni Putu Linda},
title = {The potency of blumeatin and luteolin as caspase-1 inhibitor by molecular docking},
journal = {Pharmacy Reports},
year = {2022},
doi = {10.51511/pr.22}
}
EUVIMED